Where does OCRA's clinical trial data come from?

OCRA indexes clinical trials from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Trials are matched to diseases, investigators, and funded research tracked across the platform.

How do I find clinical trials for ovarian cancer?

Search by condition, treatment type, trial phase, or NCT identifier. Each trial page shows current status, eligibility criteria, study locations, and a direct link to the ClinicalTrials.gov source record.

How often is clinical trial data updated?

Trial data is refreshed through periodic ingestion from the ClinicalTrials.gov v2 API. Status changes, new enrollments, and newly registered trials are captured during each update cycle.

Unusual Infiltrative Patterns of Malignant Cells in Endometrial Carcinoma and Immunohistochemical Expression of P53

NCT05755893UNKNOWNOBSERVATIONAL

Summary

The goal of this observational study is to clarify the significance of TB, PDC, DR, MELF, and immunohistochemical expression of those infiltrative patterns in patients with endometrial carcinomas (EC). The main questions it aims to answer are: 1. What is the relationship between TB, PDC, DR, MELF, and other clinicopathological features of patients with endometrial carcinomas (EC)? 2. What is the association of TB, PDC, DR, and MELF patterns with disease-free survival and overall survival? 3. Will the evaluation of the immunohistochemical expression of P53 in the TB, PDC, DR, and MELF patterns be important?

Key Facts

Lead Sponsor

Assiut University

Enrollment

100

Start Date

2023-04-01

Completion Date

2025-04-01

Study Type

OBSERVATIONAL

Official Title

Study of the Unusual Infiltrative Patterns of Malignant Cells and the Immunohistochemical Expression of P53 in Different Histological Types of Endometrial Carcinoma

Conditions

Endometrial Cancer

Eligibility

Age Range

20 Years – 80 Years

Sex

FEMALE

Inclusion Criteria:

1. Histologically proven Endometrial cancer specimens.
2. underwent total abdominal hysterectomy, with myometrial invasion.

Exclusion Criteria:

1. Endometrial biopsies
2. hysterectomy specimens diagnosed with different pathological lesions rather than EC.
3. Specimens with prior chemotherapy or radiotherapy.
4. specimens without myometrial invasion.

Outcome Measures

Primary Outcomes

Unusual infiltrative patterns and their IHC expression P35

Presence or absence of Tumor budding, microcystic elongated fragmented pattern, desmoplastic reaction and poorly differentiated clusters

Time frame: 2 years

Linked Papers

2021-08-26

Prognostic significance of tumor budding, poorly differentiated cluster, and desmoplastic reaction in endometrioid endometrial carcinomas

AbstractAimsThe tumor budding (TB); poorly differentiated cluster (PDC); desmoplastic reaction (DR); and microcystic, elongated, and fragmented (MELF) patterns of invasion are pathological findings at the tumor invasion front associated with epithelial‐to‐mesenchymal transition. This study aimed to clarify the clinical significance of the TB, PDC, DR, and MELF patterns in endometrioid endometrial carcinomas (EEC).MethodsTwo hundred and eight cases of histologically proven EEC retrieved from the archives of the Department of Pathology, Fukui Prefectural Hospital, and diagnosed between January 2000 and August 2020 were retrospectively analyzed.ResultsThe TB, PDC, DR, and MELF patterns were identified in 29 (13.9%), 47 (22.6%), 45 (21.6%), and 23 (11.1%) cases, respectively. Kaplan–Meier curve analysis with log‐rank test demonstrated that TB, PDC, and DR were associated with a lower progression‐free survival (p = 0.010, 0.002, and <0.0001, respectively), whereas the MELF pattern did not show any association (p = 0.668). In multivariate analyses, only DR was significantly associated with lower progression‐free survival (p = 0.034). Moreover, only PDC was associated with lower overall survival in univariate analysis (p = 0.018), but the association lost significance in multivariate analysis.ConclusionsThe present study revealed that the histological confirmation of TB, PDC, and DR at the tumor invasive front predicts poor prognosis in EEC. However, the MELF pattern was not a predictor of poor prognosis in EEC.

Linked Investigators

Megumi Yamamoto